If the team is happy to iPS cells Brian, Horizon is happy.
If you ultimately need the iPS cells to differentiate into particular cell-types as part of the programme, I can recommend a new spinout from Addenbrooke’s (DefiniGen) that has built up a large bank of iPS cells with preferred differentiation patterns (along with good differentiation protocols) that may be interested in joining to replace Cellartis. I can get in touch if this sounds of any interest.
Best Regards,
Chris
Dr Chris Torrance | CSO
Horizon Discovery Ltd, Building 7300, IQ Cambridge, Cambridge, CB25 9TL, United Kingdom
Tel: +44 (0) 1223 655 580 (Reception), +44 (0) 1223 655 582 (Direct), Fax: +44 (0) 1223 862 240
Cell: +44 (0) 7507 891133 (International)
Email: c.torrance@horizondiscovery.com Website: www.horizondiscovery.com
GENESIS TM Homologous recombination-mediated human gene-editing platform exploiting rAAV targeting vectors
X-MAN TM Gene-X Mutant & Normal, patient-relevant isogenic somatic models of human genetic diseases
This e-mail, including any attachments, is a confidential business communication, and may contain information that is confidential, proprietary and/or privileged. This e-mail is intended only for the individual(s) to whom it is addressed, and may not be saved, copied, printed, disclosed or used by anyone else. If you are not the(an) intended recipient, please immediately delete this e-mail from your computer system and notify the sender. Thank you.
Registered in England No. 05363294
Registered Office: C/O Price Bailey, The Quorum, Barnwell Road, Cambridge, CB5 8RE
VAT No: GB 91666790
From: cellfatewp9-bounces@lists.crg.es [mailto:cellfatewp9-bounces@lists.crg.es] On Behalf Of Brian Hendrich
Sent: 26 November 2012 10:44
To: cellfatewp9@lists.crg.es
Subject: [Cellfatewp9] hES in WP9
Hi All,
We need to source some human pluripotent cell lines that we can use for manipulation and analysis, given the withdrawal of Cellartis from 4DCellFate. The permits we have from both the UK and European powers that be regarding human ES cell use specify that we are only allowed to use lines that would have been provided by Cellartis. In order to use any other hES line, we'll have to modify this paperwork and await permission.
Therefore I suggest we get started using a human iPS line. To be honest I'm not sure how much benefit there is in using hES vs hiPS for these studies, given the general lack of clarity about exactly what a human "Pluripotent" cell is anyway.
Austin Smith has confirmed that he is willing to provide both an iPS and/or a hES line for our work. So, assuming no one has any objections, I'll get the iPS line and Horizon can get started targeting this line now. I can also apply to use Austin's hES line, but whether we actually use it or not depends upon whether anyone has strong reasons for doing things in hES cells rather that iPS cells.
I'd be happy to hear your thoughts on this.
Best wishes,
Brian
Brian D. Hendrich, PhD
Wellcome Trust Senior Research Fellow
Wellcome Trust-MRC Stem Cell Institute
Department of Biochemistry
University of Cambridge
Tennis Court Road
Cambridge
CB2 1QR
United Kingdom
Office: +44 (0)1223 760205
Lab: +44 (0)1223 760212
Fax: +44 (0)1223 760241